NorthStar Medical Radioisotopes has inked a deal with Ion Beam Applications (IBA) to purchase one of IBA's Rhodotron TT300 HE electron-beam accelerators for the commercial production of actinium-225 (Ac-225) at its new production facility in Beloit, WI.
Final designs are underway for the facility, which will be exclusively dedicated to Ac-225 production, NorthStar said. Initial production of Ac-225 is planned for late 2023, with a drug master file to be submitted to the U.S. Food and Drug Administration in 2024, the company said.
NorthStar's process for producing Ac-225 is free of long-life radioactive byproducts associated with other production methods, the company added.
